PHVSPharvaris N.V.

Healthcare

$31.14+23% 1Y

$31.14

$20.9652 weeks$38.97

Price

+23%1Y

End-of-day closes, not the intraday tick.

RyuScore

Weak, higher than 7% of companies

9/100

Seven criteria, weighted: see how it is built

The five questions

2 of 5 available

Only two of the five can be answered for PHVS today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.

Is the business good?not enough filed
Is it safe?Mixed
Is the price fair?not enough filed
Is it growing?not enough filed
What is the market doing?Mixed

What they do

Pharvaris is a late-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases.

In the company’s own words · 20-F filed Apr 2, 2026 · SEC EDGAR

P/En/a

Market value$2.33B

1 year+23%

5 years+64%